Brind.
  1. Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

The company Guardant Health, which has a director, is based in Palo Alto.

1 report, 1 independent Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The company Guardant Health, which has a director, is based in Palo Alto.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped